Issued on: 15/04/2026 - 14:53
Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live longer and showed an improvement in survival without worsening of the disease in a keenly anticipated late-stage trial. Patients who received the once-daily pill, daraxonrasib, showed a median overall survival of 13.2 months compared with 6.7 months for those who were given intravenous cytotoxic chemotherapy, the standard of care, the company said on Monday.
Elon Musk's SpaceX aborts booster recovery due to technical issues
Youth Olympic Games organisers hail Senegal's capability to host major events
France and Cambodia share their love for pétanque in Phnom Penh
Washington divided over how to deal with fallout from the Nvidia case
US: What exactly caused the longest nationwide ground stop in 25 years?
US Transport Secretary asks Congress for $30 bn to upgrade aviation infrastructure
USA: All passengers survive after tanker hits docked river cruise ship in New Orleans
Inside Ethiopia's war: Rare access to a hospital treating victims of renewed fighting
Who are the 'street medics' showing up at protests around the world?
U2 releases first new studio album in a decade, 'Caranaval de Luz'
The content you requested does not exist or is not available anymore.




